Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation.


Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
09 2021
Historique:
received: 01 04 2021
revised: 15 05 2021
accepted: 23 05 2021
pubmed: 1 6 2021
medline: 15 10 2021
entrez: 31 5 2021
Statut: ppublish

Résumé

Pulmonary hypertension (PH) is associated with high morbidity in children undergoing hematopoietic stem cell transplantation (HSCT). However, owing to the lack of sequential echocardiography, the nature of the condition is not fully understood. This study was conducted to investigate whether routine echocardiography performed after HSCT could detect patients with PH at an earlier stage and elucidate the role of intervention using tadalafil. The study population comprised 93 consecutive children age <18 years who underwent a total of 109 HSCTs. All patients underwent routine transthoracic echocardiography during HSCT. Four children (4%) with a median age of 4 years (range, 0.7 to 6 years) were found to have PH, and their median tricuspid regurgitation peak velocity (TRV) was 4.1 m/s (range, 3.5 to 4.2 m/s). PH was diagnosed at a median of 52 days (range, 21 to 118 days) after HSCT. Three of them were diagnosed with neuroblastoma, and 1 was diagnosed with infantile leukemia. One patient developed PH after autologous HSCT, and 3 received killer immunoglobulin-like receptor ligand-mismatched cord blood. Busulfan was used for conditioning in all patients, and the proportion of patients receiving this medication was significantly higher in the PH group compared with the non-PH group (100% versus 30%; P = .011). Three of the 4 patients had a durable response (TRV ≤2.8 m/s) at a median of 46 days (range, 14 to 79 days) after starting treatment with tadalafil. No patient experienced exacerbation of PH, and treatment was completed at median of 96 days (range, 46 to 212 days). Our data suggest that routine echocardiography monitoring after HSCT should be considered in children receiving busulfan, although the precise follow-up timing needs further study. In addition, safe and effective administration of tadalafil must be ensured by close monitoring.

Identifiants

pubmed: 34058426
pii: S2666-6367(21)00936-2
doi: 10.1016/j.jtct.2021.05.017
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

786.e1-786.e8

Informations de copyright

Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Auteurs

Nozomu Kawashima (N)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoshie Fukasawa (Y)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Eri Nishikawa (E)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Keiko Ohta-Ogo (K)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Hatsue Ishibashi-Ueda (H)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Motoharu Hamada (M)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Daisuke Ichikawa (D)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Atsushi Narita (A)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yusuke Okuno (Y)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; Genome Medical Center, Nagoya University Hospital, Nagoya, Japan.

Hideki Muramatsu (H)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Nobuhiro Nishio (N)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; Center for Advanced Medicine and Clinical Research, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

Seiji Kojima (S)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Taichi Kato (T)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoshiyuki Takahashi (Y)

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: ytakaha@med.nagoya-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH